Get the Stockscreener App
4.00
3.09%
0.12
After Hours:
4.01
0.010
+0.25%
X 4 Pharmaceuticals Inc stock is traded at $4.00, with a volume of 501.51K.
It is up +3.09% in the last 24 hours and down -7.83% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.88
Open:
$3.93
24h Volume:
501.51K
Relative Volume:
1.26
Market Cap:
$377.28M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.8814
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
+4.44%
1M Performance:
-7.83%
6M Performance:
+2.30%
1Y Performance:
+31.15%
1-Day Range:
$3.90
$4.02
1-Week Range:
$3.66
$4.02
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.00 | 377.28M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
KalVista (NASDAQ: KALV) CMO’s stock, RSUs and options cancelled in $27-per-share Chiesi merger cleanup - Stock Titan
KalVista (KALV) director has 45,000 stock options cashed out in Chiesi merger terms - Stock Titan
KalVista (NASDAQ: KALV) director’s options canceled and cashed out in $27 Chiesi deal - Stock Titan
KalVista (KALV) CCO Sweeny cashes out stock, RSUs and options in Chiesi buyout - Stock Titan
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger - Stock Titan
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart - Stock Titan
KalVista (NASDAQ: KALV) CEO equity cancelled for $27 cash deal - Stock Titan
KalVista (NASDAQ: KALV) CDO disposes equity in $27-per-share Chiesi deal - Stock Titan
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes - Stock Titan
Vivo Opportunity entities (INM) add 249,227 InMed shares in open-market buys - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - TradingView
Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin - JD Supra
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
Layoff Tracker: Fulcrum axes 85% of staff after walking away from lead asset - BioSpace
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | MintzIntellectual Property Viewpoints - JD Supra
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - markets.businessinsider.com
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ADHD medication shortage reported by pharmaceutical companies - FOX Carolina News
XFOR: Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028 - TradingView
Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives - Newsweek
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
XFOR Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink initiates X4 Pharmaceuticals stock with outperform rating - Investing.com
Leerink Partners Initiates X4 Pharmaceuticals(XFOR.US) With Buy Rating, Announces Target Price $12 - Moomoo
Leerink Partners Initiates X4 Pharmaceuticals at Outperform With $12 Price Target - marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FULL HOUSE RESORTS TO BREAK GROUND ON THE PERMANENT AMERICAN PLACE CASINO - Weekly Voice
New hires at rare-disease drugmaker get 160,000 stock options - Stock Titan
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Fennec Pharmaceuticals (FENC) CEO receives 1,159-share stock award - Stock Titan
Trump Is Being Sued For Rescheduling Marijuana By Doctors And A Pharmaceutical Company Who Are 'Aggrieved' By The Move - Marijuana Moment
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals (XFOR) Gains 2.73% as Stock Tests Key Resistance LevelsRating Change - The Legal Advocate
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):